• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients.一种源自β-微管蛋白5的肽可诱导前列腺癌患者体内受HLA-A24等位基因限制的细胞毒性T淋巴细胞。
Exp Ther Med. 2010 Sep;1(5):833-839. doi: 10.3892/etm.2010.120. Epub 2010 Jul 20.
2
Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.在 HLA - A3 +、- A11 +、- A31 +和 - A33 +癌症患者中共享的肽疫苗候选物的鉴定。
Clin Cancer Res. 2004 Feb 1;10(3):1112-20. doi: 10.1158/1078-0432.ccr-0797-3.
3
Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.鉴定携带HLA - A3超型等位基因的前列腺癌患者的肽疫苗候选物。
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6933-43. doi: 10.1158/1078-0432.CCR-05-0682.
4
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.一种与HLA - A3结合的前列腺酸性磷酸酶衍生肽可诱导受限于HLA - A2和 - A24等位基因的细胞毒性T淋巴细胞。
Cancer Immunol Immunother. 2009 Nov;58(11):1877-85. doi: 10.1007/s00262-009-0699-2. Epub 2009 Mar 28.
5
New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.具有在携带HLA - A3超型等位基因的前列腺癌患者中诱导癌症反应性细胞毒性T淋巴细胞潜力的新型多梳蛋白zeste同源物（EZH）2衍生肽。
Int Immunopharmacol. 2015 May;26(1):133-8. doi: 10.1016/j.intimp.2015.03.023. Epub 2015 Mar 27.
6
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.鉴定适用于具有人类白细胞抗原 - A3超型等位基因患者的抗癌疫苗的Lck衍生肽。
Br J Cancer. 2007 Dec 17;97(12):1648-54. doi: 10.1038/sj.bjc.6604071. Epub 2007 Nov 27.
7
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.鉴定具有从携带HLA - A3超型等位基因的前列腺癌患者中诱导癌症反应性细胞毒性T淋巴细胞潜力的源自SART3的肽。
Cancer Immunol Immunother. 2007 May;56(5):689-98. doi: 10.1007/s00262-006-0216-9. Epub 2006 Aug 26.
8
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.SART3(109 - 118)肽诱导具有HLA I类A11、A31和A33等位基因的前列腺癌患者产生细胞毒性T淋巴细胞的能力。
Int J Oncol. 2009 Feb;34(2):529-36.
9
Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals.跨等位基因细胞毒性 T 淋巴细胞对 HLA-A24 和 HLA-A3 超型阳性个体中 2009 年甲型 H1N1 流感病毒的反应。
J Virol. 2012 Dec;86(24):13281-94. doi: 10.1128/JVI.01841-12. Epub 2012 Sep 26.
10
New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.针对具有HLA - A3超型等位基因的上皮癌患者的新型肽疫苗候选物。
J Immunother. 2007 Apr;30(3):274-81. doi: 10.1097/01.cji.0000211340.88835.e7.

引用本文的文献

1
Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.根治性放疗对局限性前列腺癌患者免疫状态的影响。
Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018.

本文引用的文献

1
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.一项个体化肽疫苗联合低剂量雌莫司汀磷酸酯（EMP）与标准剂量 EMP 治疗去势抵抗性前列腺癌的随机 II 期临床试验。
Cancer Immunol Immunother. 2010 Jul;59(7):1001-9. doi: 10.1007/s00262-010-0822-4. Epub 2010 Feb 10.
2
Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.鉴定适用于 HLA - A26 阳性癌症患者的肽类疫苗。
Cancer Sci. 2009 Nov;100(11):2167-74. doi: 10.1111/j.1349-7006.2009.01298.x. Epub 2009 Jul 23.
3
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles.一种源自丙型肝炎病毒（HCV）核心蛋白的肽，可在具有各种HLA I类A等位基因的HCV患者中诱导细胞反应。
J Med Virol. 2009 Jul;81(7):1232-40. doi: 10.1002/jmv.21518.
4
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.一种与HLA - A3结合的前列腺酸性磷酸酶衍生肽可诱导受限于HLA - A2和 - A24等位基因的细胞毒性T淋巴细胞。
Cancer Immunol Immunother. 2009 Nov;58(11):1877-85. doi: 10.1007/s00262-009-0699-2. Epub 2009 Mar 28.
5
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.SART3(109 - 118)肽诱导具有HLA I类A11、A31和A33等位基因的前列腺癌患者产生细胞毒性T淋巴细胞的能力。
Int J Oncol. 2009 Feb;34(2):529-36.
6
Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas.非小细胞肺癌中β-微管蛋白II型和V型的表达模式
Cell Motil Cytoskeleton. 2008 Aug;65(8):675-85. doi: 10.1002/cm.20297.
7
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.鉴定适用于具有人类白细胞抗原 - A3超型等位基因患者的抗癌疫苗的Lck衍生肽。
Br J Cancer. 2007 Dec 17;97(12):1648-54. doi: 10.1038/sj.bjc.6604071. Epub 2007 Nov 27.
8
The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.HLA-A*0201限制性次要组织相容性抗原HA-1H肽也可由另一种HLA-A2亚型A*0206呈递。
Bone Marrow Transplant. 2007 Jul;40(2):165-74. doi: 10.1038/sj.bmt.1705689. Epub 2007 May 28.
9
New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.针对具有HLA - A3超型等位基因的上皮癌患者的新型肽疫苗候选物。
J Immunother. 2007 Apr;30(3):274-81. doi: 10.1097/01.cji.0000211340.88835.e7.
10
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.鉴定具有从携带HLA - A3超型等位基因的前列腺癌患者中诱导癌症反应性细胞毒性T淋巴细胞潜力的源自SART3的肽。
Cancer Immunol Immunother. 2007 May;56(5):689-98. doi: 10.1007/s00262-006-0216-9. Epub 2006 Aug 26.

一种源自β-微管蛋白5的肽可诱导前列腺癌患者体内受HLA-A24等位基因限制的细胞毒性T淋巴细胞。

A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients.

作者信息

Komatsu Nobukazu, Terasaki Yasunobu, Moriya Fukuko, Suekane Shigetaka, Noguchi Masanori, Todo Satoru, Itoh Kyogo, Shichijo Shigeki

机构信息

Departments of Immunology and Immunotherapy, and.

出版信息

Exp Ther Med. 2010 Sep;1(5):833-839. doi: 10.3892/etm.2010.120. Epub 2010 Jul 20.

DOI:10.3892/etm.2010.120
PMID:22993607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3445947/
Abstract

To facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce HLA-class I-restricted cytotoxic T lymphocyte (CTL) activity in HLA-A3 supertype (-A3, -A11, -A31 and -A33)-positive prostate cancer patients are also capable of inducing CTLs restricted to HLA-A2, HLA-A24 or HLA-A26 alleles. Among the 13 peptides tested, a peptide at positions 309 to 318 of β-tubulin 5 exhibited binding activity to the HLA-A(*)2402 molecule and induced HLA-A24-restricted CTL activity against prostate cancer cells derived from peripheral blood mononuclear cells of prostate cancer patients. The CTL activity was determined to be specific to this peptide and was mediated by CD8(+) T cells in an HLA-class I-restricted manner. These results suggest that this peptide could be applicable as a peptide vaccine, not only for HLA-A3 supertype-positive, but also for HLA-A24-positive prostate cancer patients.

摘要

为推动用于前列腺癌患者的基于肽的癌症疫苗的研发，我们研究了先前报道的在HLA - A3超型（-A3、-A11、-A31和 - A33）阳性前列腺癌患者中诱导HLA - I类限制性细胞毒性T淋巴细胞（CTL）活性的13种肽是否也能够诱导受HLA - A2、HLA - A24或HLA - A26等位基因限制的CTL。在所测试的13种肽中，β - 微管蛋白5第309至318位的一种肽表现出与HLA - A(*)2402分子的结合活性，并诱导针对源自前列腺癌患者外周血单个核细胞的前列腺癌细胞的HLA - A24限制性CTL活性。确定该CTL活性对此肽具有特异性，并且以HLA - I类限制性方式由CD8(+) T细胞介导。这些结果表明，该肽不仅可作为肽疫苗用于HLA - A3超型阳性的前列腺癌患者，也可用于HLA - A24阳性的前列腺癌患者。